drugset / Trial / NCT05050006
ITIL-168 in Advanced Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).
Timeline
- Start
- 2021-10-07
- Primary completion
- 2023-02-27
- Completion
- 2023-02-27
Outcome
Outcome not reported
Stopped (Business): “Business Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ITIL-168 | Cell therapy | — | — |